Aerie Pharmaceuticals (NASDAQ:AERI) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.
Other equities analysts also recently issued reports about the stock. Canaccord Genuity set a $65.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th. JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $62.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. Finally, Mizuho reaffirmed a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $71.43.
Aerie Pharmaceuticals (AERI) opened at $61.40 on Tuesday. Aerie Pharmaceuticals has a one year low of $35.50 and a one year high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.